AI3 Bio, Inc. has filed a new offering under Rule 506(b) of the Securities Act, which provides a "safer harbor" for private offerings. This filing, dated November 4, 2026, signifies the company's ongoing efforts to expand its operations within the biotechnology sector.

As part of this offering, AI3 Bio has confirmed that all shares of capital stock of Novasenta, Inc. held by accredited investors were exchanged for shares of AI3 Bio, based on an exchange ratio determined pursuant to the terms of the merger agreement dated June 9, 2026. This strategic move may position AI3 Bio for growth in a competitive market.

Background

AI3 Bio, Inc. is a biotechnology company based in Watertown, Massachusetts. The company was previously known as Corner Therapeutics, Inc. and changed its name on April 15, 2024. The firm operates under the Central Index Key (CIK) of 0002019875 and has been active in filing various forms with the SEC, including recent filings on November 4, 2026, and prior forms in October and August of the same year.

What the Filing Says

The filing states, "Pursuant to an Agreement and Plan of Merger dated as of June 9, 2026, all shares of capital stock of Novasenta, Inc. held by accredited investors were exchanged for shares of the Issuer." This indicates a significant business combination transaction aimed at enhancing AI3 Bio's market position.

Impact

This development may affect the company’s existing investors and potential investors, as well as competitors in the biotechnology sector. The filing notes that the offering has a total offering amount described as indefinite, which may suggest a flexible approach to raising capital.

What's Next

The filing does not say what happens next.